<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02254174</url>
  </required_header>
  <id_info>
    <org_study_id>1184.11</org_study_id>
    <nct_id>NCT02254174</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers</brief_title>
  <official_title>A Randomised, Open-label Four-way Crossover Study to Evaluate Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Single Dose (7.5 μg Tiotropium, 25 μg Salmeterol, Inhalation Powder, Hard Capsule, HandiHaler®2), a Free Combined Single Dose of 18 μg Tiotropium [Spiriva® HandiHaler®] and 50 μg Salmeterol [Serevent® Diskus®], a Single Dose of 50μg Salmeterol (Serevent® Diskus®) and a Single Dose of 18 μg Tiotropium (Spiriva® HandiHaler®) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Assessment of the relative bioavailability of a fixed dose combination of tiotropium and&#xD;
      salmeterol compared to a free dose combination of the marketed products of tiotropium and&#xD;
      salmeterol (Spiriva® and Serevent® Diskus®).&#xD;
&#xD;
      Assessment of the relative bioavailability of a fixed dose combination of tiotropium and&#xD;
      salmeterol compared to tiotropium and salmeterol administered as individual mono substances&#xD;
      from the marketed products.&#xD;
&#xD;
      Assessment of safety and tolerability of the fixed combination of tiotropium and salmeterol&#xD;
      in a PE (Polyethylene) capsule administered via the HandiHaler® 2&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of salmeterol in blood plasma over the time interval from 0 extrapolated to infinity);</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of salmeterol in blood plasma)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ae0-8 (urinary excretion of tiotropium over an 8 hour interval)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of tiotropium in blood plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of tiotropium in blood plasma)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt1-t2 (area under the concentration time curve in plasma over the time interval t1 to t2)</measure>
    <time_frame>up to 8 hours after inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of in plasma)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant in plasma)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ (terminal half-life of in plasma)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTih (mean residence time in the body after inhalational administration)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of in the plasma after extravascular administration)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2</measure>
    <time_frame>up to 8 hours after inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)</measure>
    <time_frame>up to 8 hours after inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)</measure>
    <time_frame>up to 8 hours after inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal findings in physical examination</measure>
    <time_frame>up to 90 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs</measure>
    <time_frame>up to 90 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal findings in 12-lead ECG</measure>
    <time_frame>up to 90 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal changes in clinical laboratory parameters</measure>
    <time_frame>up to 90 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 90 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability assessed by investigator on a 4-point scale</measure>
    <time_frame>up to 90 days after first drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tiotropium/Salmeterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Serevent® Diskus®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spiriva®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spiriva® and Serevent® Diskus®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium/Salmeterol</intervention_name>
    <description>Fixed dose combination of tiotropium 7.5 μg and salmeterol 25 μg inhalation powder, PE capsule via HandiHaler®</description>
    <arm_group_label>Tiotropium/Salmeterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serevent® Diskus®</intervention_name>
    <arm_group_label>Serevent® Diskus®</arm_group_label>
    <arm_group_label>Spiriva® and Serevent® Diskus®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spiriva®</intervention_name>
    <arm_group_label>Spiriva®</arm_group_label>
    <arm_group_label>Spiriva® and Serevent® Diskus®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male based upon a complete medical history, including the physical&#xD;
             examination, regarding vital signs (blood pressure (BP), pulse rate (PR)), 12-lead ECG&#xD;
             (electrocardiogram) measurement, and clinical laboratory tests. There is no finding&#xD;
             deviating from normal and of clinical relevance.&#xD;
&#xD;
             There is no evidence of a clinically relevant concomitant disease&#xD;
&#xD;
          2. Age ≥21 and ≤50 years&#xD;
&#xD;
          3. BMI ≥18.5 and &lt;30 kg/m2 (Body Mass Index)&#xD;
&#xD;
          4. Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with GCP (Good Clinical Practice) and the local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any finding of the medical examination (including BP, PR, and ECG measurements)&#xD;
             deviating from normal and of clinical relevance&#xD;
&#xD;
          2. Evidence of a clinically relevant concomitant disease&#xD;
&#xD;
          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or&#xD;
             neurological disorders&#xD;
&#xD;
          5. History of relevant orthostatic hypotension, fainting spells or blackouts&#xD;
&#xD;
          6. Chronic or relevant acute infections&#xD;
&#xD;
          7. History of relevant allergy/hypersensitivity (including allergy to the drug or its&#xD;
             excipients) as judged clinically relevant by the investigator&#xD;
&#xD;
          8. Intake of drugs with a long half-life (&gt;24 hours) within at least 1 month or less than&#xD;
             10 half-lives of the respective drug prior to randomisation&#xD;
&#xD;
          9. Use of drugs which might reasonably influence the results of the trial based on the&#xD;
             knowledge at the time of protocol preparation within 10 days prior to enrolment in the&#xD;
             study or during the study&#xD;
&#xD;
         10. Participation in another trial with an investigational drug within 2 months prior to&#xD;
             randomisation&#xD;
&#xD;
         11. Smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day)&#xD;
&#xD;
         12. Inability to refrain from smoking on trial days as judged by the investigator&#xD;
&#xD;
         13. Alcohol abuse (more than 40 g alcohol a day)&#xD;
&#xD;
         14. Drug abuse&#xD;
&#xD;
         15. Blood donation (more than 100 mL blood within 4 weeks prior to randomisation or during&#xD;
             the trial)&#xD;
&#xD;
         16. Excessive physical activities within 1 week prior to randomisation or during the trial&#xD;
&#xD;
         17. Any laboratory value outside the reference range that is of clinical relevance&#xD;
&#xD;
         18. Inability to comply with dietary regimen of the study centre&#xD;
&#xD;
             The following exclusion criteria are specific for this study due to the known class&#xD;
             side effect profile of ß2-mimetics:&#xD;
&#xD;
         19. Asthma or history of pulmonary hyperreactivity&#xD;
&#xD;
         20. Hyperthyrosis&#xD;
&#xD;
         21. Allergic rhinitis in need of treatment&#xD;
&#xD;
         22. Clinically relevant cardiac arrhythmia&#xD;
&#xD;
         23. Paroxysmal tachycardia (&gt;100 beats per minute)&#xD;
&#xD;
             The following exclusion criteria are specific for this study due to the known class&#xD;
             side effect profile of tiotropium:&#xD;
&#xD;
         24. Hypersensitivity to tiotropium and/or related drugs of this class&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>September 30, 2014</last_update_submitted>
  <last_update_submitted_qc>September 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02254174
org study id: 1184.11
nct id: NCT02254174
lead sponsor: 
Assessment of the relative bioavailability of a fixed dose combination of tiotropium and
      salmeterol compared to a free dose combination of the marketed products of tiotropium and
      salmeterol (Spiriva® and Serevent® Diskus®).

      Assessment of the relative bioavailability of a fixed dose combination of tiotropium and
      salmeterol compared to tiotropium and salmeterol administered as individual mono substances
      from the marketed products.

      Assessment of safety and tolerability of the fixed combination of tiotropium and salmeterol
      in a PE (Polyethylene) capsule administered via the HandiHaler® 2
allocation: Randomized
intervention model: Crossover Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: AUC0-∞ (area under the concentration-time curve of salmeterol in blood plasma over the time interval from 0 extrapolated to infinity);
time frame: Up to 8 hours after drug administration
measure: Cmax (maximum measured concentration of salmeterol in blood plasma)
time frame: Up to 8 hours after drug administration
measure: Ae0-8 (urinary excretion of tiotropium over an 8 hour interval)
time frame: Up to 8 hours after drug administration
measure: AUC0-tz (area under the concentration-time curve in plasma over the time interval from 0 to the time of the last quantifiable data point)
time frame: Up to 8 hours after drug administration
measure: AUC0-∞ (area under the concentration-time curve of tiotropium in blood plasma over the time interval from 0 extrapolated to infinity)
time frame: Up to 8 hours after drug administration
measure: Cmax (maximum measured concentration of tiotropium in blood plasma)
time frame: Up to 8 hours after drug administration
measure: AUCt1-t2 (area under the concentration time curve in plasma over the time interval t1 to t2)
time frame: up to 8 hours after inhalation
measure: tmax (time from dosing to the maximum concentration of in plasma)
time frame: Up to 8 hours after drug administration
measure: λz (terminal rate constant in plasma)
time frame: Up to 8 hours after drug administration
measure: t½ (terminal half-life of in plasma)
time frame: Up to 8 hours after drug administration
measure: MRTih (mean residence time in the body after inhalational administration)
time frame: Up to 8 hours after drug administration
measure: CL/F (apparent clearance of in the plasma after extravascular administration)
time frame: Up to 8 hours after drug administration
measure: Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
time frame: Up to 8 hours after drug administration
measure: Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2
time frame: up to 8 hours after inhalation
measure: fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)
time frame: up to 8 hours after inhalation
measure: CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)
time frame: up to 8 hours after inhalation
measure: Number of participants with abnormal findings in physical examination
time frame: up to 90 days after first drug administration
measure: Number of participants with clinically significant changes in vital signs
time frame: up to 90 days after first drug administration
measure: Number of participants with abnormal findings in 12-lead ECG
time frame: up to 90 days after first drug administration
measure: Number of participants with abnormal changes in clinical laboratory parameters
time frame: up to 90 days after first drug administration
measure: Number of participants with adverse events
time frame: up to 90 days after first drug administration
measure: Tolerability assessed by investigator on a 4-point scale
time frame: up to 90 days after first drug administration
arm group label: Tiotropium/Salmeterol
arm group type: Experimental
arm group label: Serevent® Diskus®
arm group type: Active Comparator
arm group label: Spiriva®
arm group type: Active Comparator
arm group label: Spiriva® and Serevent® Diskus®
arm group type: Active Comparator
intervention type: Drug
intervention name: Tiotropium/Salmeterol
description: Fixed dose combination of tiotropium 7.5 μg and salmeterol 25 μg inhalation powder, PE capsule via HandiHaler®
arm group label: Tiotropium/Salmeterol
intervention type: Drug
intervention name: Serevent® Diskus®
arm group label: Serevent® Diskus®
arm group label: Spiriva® and Serevent® Diskus®
intervention type: Drug
intervention name: Spiriva®
arm group label: Spiriva®
arm group label: Spiriva® and Serevent® Diskus®
criteria: 
gender: Male
minimum age: 21 Years
maximum age: 50 Years
healthy volunteers: Accepts Healthy Volunteers
url: http://trials.boehringer-ingelheim.com
description: Related Info
responsible party type: Sponsor
mesh term: Respiratory Aspiration
mesh term: Tiotropium Bromide
mesh term: Salmeterol Xinafoate